Prelude Therapeutics Incorporated
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
PRLD · Price history
Price at last available close
$4.07
+$0.16 (+3.96%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Prelude Therapeutics Incorporated
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme.
How they make money
Prelude Therapeutics is a clinical-stage precision oncology company that generates revenue primarily through research and development collaboration agreements. These agreements typically involve upfront payments, milestone payments upon the achievement of specific clinical or regulatory goals, and potential future royalties from the commercialization of licensed drug candidates.
Products & services
The company focuses on the discovery and development of small molecule therapies and next-generation degrader antibody conjugates (DACs) targeting cancer, including KAT6A degraders and JAK2V617F mutant selective inhibitors.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Pharmaceutical and biotechnology companiesSource
Customer concentration
The company's revenue is derived from a limited number of collaboration partners, leading to significant customer concentration. For the year ended December 31, 2025, revenue was concentrated among a small number of strategic partners.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party providers for clinical trial management, data collection, and the manufacturing of drug substances and products for clinical use. Specific supplier names are not disclosed.Source
Strengths
- Proprietary precision oncology platform focused on targeted protein degradationSource
Sources
Company-specific research
Questions worth answering for PRLD
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can PRLD maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can PRLD fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does PRLD's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for PRLD to reach sustainable profitability?
- •What future growth or profitability would be needed to justify PRLD's current valuation?
Essential Investment Snapshot
Market Cap
$235.0M
P/E Ratio
-4.1
EPS
$-0.79
52-Week High
$6.83
52-Week Low
$1.16
Beta
0.96
Analyst Target
$8.00
Shares Outstanding
77.0M
Total Debt
$17.6M
Dividend
No current dividend
Liquidation Value / Share
$1.74
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on PRLD.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary precision oncology platform focused on targeted protein degradation.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of continued losses.
- −Dependence on the success of clinical-stage product candidates.
- −Reliance on third-party manufacturers and clinical trial sites.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$4.06
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +73.4%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.4M | $12.1M | $7.0M | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $2.1M | $1.7M | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $20.3M | $10.4M | $7.0M | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $69.4M | $94.3M | $118.0M | $103.4M | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $20.0M | $22.4M | $28.7M | $28.9M | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $87.7M | $115.0M | $146.7M | $132.3M | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$58.9M | -$97.8M | -$125.4M | -$120.7M | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$67.4M | -$104.6M | -$139.7M | -$132.3M | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$60.5M | -$99.5M | -$127.2M | -$121.8M | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$60.5M | -$99.5M | -$127.2M | -$121.8M | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.73 | $-1.29 | $-1.68 | $-2.02 | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 98.39M | 76.96M | 75.81M | 60.36M | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 98.39M | 76.96M | 75.81M | 60.36M | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$5.7M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.14
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-1.5%
Cash Change
+2.2%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included cash levels, debt levels. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 65.9%. Cash increased 2.2%. Total debt declined 1.5%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Prelude Therapeutics to Participate in the Chardan Healthcare Conference
Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
Head to Head Review: Surrozen (NASDAQ:SRZN) and Prelude Therapeutics (NASDAQ:PRLD)
Rumor Mill · PRLD
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial